Gary Peck, MD
Dermatology · Chevy Chase, MDNPI 1710933890
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,600 of the $14,131 with a category attached, or 89.2%. Barco, Inc. accounts for 89.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2020 at $12,711 and has fallen 99.8% since, to $28 in 2025.
Across 70 payments — averaging $201.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Barco, Inc.$13K
- Johnson & Johnson$398
- E.r. Squibb & Sons, L.L.C.$139
- Lilly USA, LLC$110
- Kerecis Limited$106
- Pfizer$90
- plus $688 from 17 others
What the payments were for
- Consulting fees$12,60089%
- Food & beverage$1,43610%
- Education$951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Barco, Inc. | 1 | $12,600 |
| Johnson & Johnson | 14 | $398 |
| E.r. Squibb & Sons, L.L.C. | 7 | $139 |
| Lilly USA, LLC | 6 | $110 |
| Kerecis Limited | 3 | $106 |
| Pfizer | 4 | $90 |
| Incyte Corporation | 4 | $88 |
| Amgen | 2 | $62 |
| Sanofi | 3 | $61 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $57 |
| Boehringer Ingelheim | 2 | $51 |
| Dermavant Sciences, Inc. | 3 | $49 |
| Sun Pharmaceutical Industries Inc. | 3 | $45 |
| Almirall LLC | 2 | $43 |
| VYNE Pharmaceuticals Inc. | 3 | $41 |
| Mission Pharmacal Company | 2 | $35 |
| Galderma Laboratories, L.p. | 2 | $34 |
| LEO Pharma Inc. | 1 | $31 |
| Biofrontera Inc. | 1 | $21 |
| Organogenesis Inc. | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Dermira, Inc. | 1 | $16 |
| Smith+Nephew | 1 | $15 |
How this compares
$14,131 in reported general payments places this provider in the 85th percentile of 306 dermatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluocinonide | 17 | $581 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Chevy Chase
- Rebecca KazinChevy Chase$342K
- Alison EhrlichChevy Chase$163K
- Pantea TamjidiChevy Chase$100K
- Mana OgholikhanChevy Chase$13K
- Benjamin LockshinSilver Spring$4M
- Shawn KwatraBaltimore$1.1M
- Chesahna Kindred WeaverMarriottsville$837K
- Oanh LauringNottingham$763K
- Ronald PrussickN Bethesda$620K
- Susan WalkerBethesda$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.